Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05892770 · ClinicalTrials.gov registry record · Phase 1
Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia
A Phase 1 study of Spasmodic Dysphonia, sponsored by University of Florida.
- Active
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05892770: Active Phase 1 study of Spasmodic Dysphonia, sponsored by University of Florida.
NCT05892770 is a Phase 1 study of Spasmodic Dysphonia that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 36 participants, below the 109-participant average among 7 other Spasmodic Dysphonia trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05892770, a Phase 1 study of Spasmodic Dysphonia, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
One initial study has shown that Botulinum Toxin (BT) in combination with zinc supplementation may increase the duration of effects BT treatment. This initial study was in the context of facial aesthetics. The purpose of the present study is to determine the effect, if any, of oral zinc supplementation prior to BT in the treatment of spasmodic dysphonia. If positive effects will be observed, this would help reduce the burden of disease for these patients.
Primary Outcome
10 question, validated survey to assess quality of voice of patients with spasmodic dysphonia. The overall V-RQOL score ranges from 10 to 15 (excellent), 16 to 20 (very good), 21 to 25 (good), 26-30 (fair) and scores more than 30 and up to 50 is poor.
Conditions Studied
Interventions
- DRUG Botulinum toxin type A
- DRUG Zinc gluconate supplement
Study Locations (1)
Florida
- University of Florida- Shands Hospital - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT05892770 still lists
NCT05892770 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 109-participant average among 7 other Spasmodic Dysphonia trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Spasmodic Dysphonia appearing as the primary indexed condition, and to 2 interventions - of which Botulinum toxin type A is the first listed.
NCT05892770 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05892770 about?
NCT05892770 is a clinical study titled "Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia". One initial study has shown that Botulinum Toxin (BT) in combination with zinc supplementation may increase the duration of effects BT treatment. This initial study was in the context of facial aesthetics. The purpose of the present study is to determine the effect, if any, of oral zinc supplementat...
What is the current status of trial NCT05892770?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-08-01. Estimated completion is 2025-12.
What conditions does trial NCT05892770 study?
This clinical trial studies the following conditions: Spasmodic Dysphonia.
What interventions are being tested in trial NCT05892770?
The interventions under investigation include: Botulinum toxin type A (DRUG), Zinc gluconate supplement (DRUG).
Who is sponsoring clinical trial NCT05892770?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05892770 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spasmodic Dysphonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor
RECRUITING
-
Brain Networks in Dystonia
RECRUITING
-
Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor
RECRUITING · Early Phase 1
-
Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor
RECRUITING · NA
-
Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia
COMPLETED
-
Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI